Minimising treatment-associated risks in systemic cancer therapy.
about
Does applying technology throughout the medication use process improve patient safety with antineoplastics?Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?Evaluation of clinical interventions made by pharmacists in chemotherapy preparation.Agreement between pharmacists for problem identification: an initial quality measurement of cognitive services.Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.Evaluation of Supportive Care Management Outcomes in Cancer Chemotherapy: A Prospective Observational Study in a Tertiary Care Teaching Hospital in South India.
P2860
Minimising treatment-associated risks in systemic cancer therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Minimising treatment-associated risks in systemic cancer therapy.
@ast
Minimising treatment-associated risks in systemic cancer therapy.
@en
Minimising treatment-associated risks in systemic cancer therapy.
@nl
type
label
Minimising treatment-associated risks in systemic cancer therapy.
@ast
Minimising treatment-associated risks in systemic cancer therapy.
@en
Minimising treatment-associated risks in systemic cancer therapy.
@nl
prefLabel
Minimising treatment-associated risks in systemic cancer therapy.
@ast
Minimising treatment-associated risks in systemic cancer therapy.
@en
Minimising treatment-associated risks in systemic cancer therapy.
@nl
P2093
P2860
P1476
Minimising treatment-associated risks in systemic cancer therapy.
@en
P2093
Andrea Liekweg
Martina Westfeld
Sven Simons
Ulrich Jaehde
P2860
P304
P356
10.1007/S11096-007-9157-4
P407
P577
2007-09-29T00:00:00Z
2008-04-01T00:00:00Z